Tag: HIV

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).

Combined Treatment for HIV and Visceral Leishmaniasis Coinfection

A combination of AmBisome monotherapy and miltefosine could be beneficial when treating a coinfection of HIV and visceral leishmaniasis. In at least 35 countries, in four different continents, coin...

Global Fund Plans to Rise $14bn for AIDS, TB, Malaria Fight

An international health fund that finances the fight against acquired immune deficiency syndrome (AIDS), tuberculosis (TB) and malaria has announced a $14bn fundraising target for the next three years...

Genetic Immunity presented its immunotherapy platform in Russia

clinical trials
Genetic Immunity announced that it was invited to present at the first Russian-Chinese HIV Congress in Moscow (Russia).

MSD receives EU approval for two HIV medicines

MSD (known as Merck in the USA and Canada) announced that the European Commission has approved DELSTRIGO and PIFELTRO for the treatment of HIV-1 infection.

EECA states join their efforts in fight against communicable diseases

Minsk is hosting the Eastern Europe and Central Asia (EECA) Regional Consultation on Expanding Access to Affordable and Quality Assured Antiretroviral and Antituberculosis Medicines.

Belarus is hosting the second EECA consultation on ARV and TB drugs

Belarus' Deputy Premier, spoke at the Eastern Europe and Central Asia Regional Consultation on Expanding Access to Affordable and Quality Assured ARV and TB Medicines in Minsk.

An injection drug for HIV-infected patients may appear in 4 years

A new drug for antiretroviral therapy is undergoing clinical trials at the Central Research Institute of Epidemiology. It may become commercially available not earlier than in four years.

Gilead localizes the production of hepatitis C and HIV drugs in Russia

According to the agreement Pharmstandard production facilities will manufacture Sovaldi® for the treatment of chronic hepatitis C and Truvada® for the treatment of HIV.

First Chinese HIV drug is approved for human clinical trials in USA

clinical trials
Chinese first domestically-made anti-HIV drug has been given approval by the US Food and Drug Administration (FDA) to begin the next phase of clinical trials in America.

Viriom intends to produce Elpida at the facilities of Pharmstandard

JSC Pharmstandard, a Russian pharmaceutical industry leader, and Viriom LLC, a company engaged in the development of innovative medicines, signed an agreement on intentions.

Yale scientists contrived a promising HIV therapy

In a study, a new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection.

ViiV Healthcare unveiled positive results from trial of two-drug HIV regimen

viiv healthcare
ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR) for the treatment of HIV.

Gilead’s HIV treatment obtained EU marketing authorization

Gilead Sciences announced that the European Commission has granted Marketing Authorization for Biktarvy®, a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.

Gilead and Hookipa Biotech will develop HIV and Hepatitis B treatments

gilead sciences
Hookipa Biotech AG, an Austrian clinical-stage biotech company, and Gilead Sciences, a research-based biopharmaceutical company, entered into a research collaboration and license agreement.

ViiV Healthcare’s HIV treatment showed positive results in phase III studies

viiv healthcare
The GEMINI studies are part of innovative clinical trial programme for two-drug regimens that seeks to address long-term toxicity concerns of people living with HIV by reducing the number of medicines used in their treatment.

China Food and Drug Administration approved a new HIV drug

China Food and Drug Administration (FDA) has approved the sale of a new drug for the treatment of HIV-1 infection, the maker of the drug said.